Frontiers in Medical Science Research, 2025, 7(4); doi: 10.25236/FMSR.2025.070408.
Shanle Zhou1, Jianxin Lyu2
1College of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China
2Key Laboratory of Laboratory Medicine, Ministry of Education, College of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China
This study is dedicated to investigating the effects of the GSPT1 inhibitor MRT-2359 on the functional modulation of immune cells in the context of non-small cell lung carcinoma and to elucidate the underlying mechanisms. Accumulating evidence has highlighted the aberrant upregulation of eRF3a/GSPT1 across a spectrum of malignancies, positioning GSPT1 as a highly promising target for therapeutic intervention. Our findings demonstrate that MRT-2359 efficaciously induces the degradation of GSPT1 within NSCLC cells. Utilizing RNA sequencing (RNA-seq) and other advanced molecular techniques, we have postulated that MRT-2359 modulates the expression of CD276, thereby suppressing the tumor immune evasion phenotype of NSCLC cells. In vivo studies corroborate the tumor-suppressive effects of MRT-2359 in murine models, with immunohistochemical analyses revealing a significant reduction in GSPT1 and CD276 within tumor tissues. Concurrently, an enhanced infiltration of granzyme B (GZMB)-positive cells was observed. These collective findings provide reference value for MRT-2359 advancement towards clinical application.
GSPT1, MRT-2359, CD276, Non-Small Cell Lung Cancer, Immune Escape
Shanle Zhou, Jianxin Lyu. Mechanism Study of the Effect of GSPT1 Inhibitor MRT-2359 on Immune Escape in Non-Small Cell Lung Cancer. Frontiers in Medical Science Research (2025), Vol. 7, Issue 4: 63-71. https://doi.org/10.25236/FMSR.2025.070408.
[1] MOLINA J R, YANG P, CASSIVI S D, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship [J]. Mayo Clinic proceedings, 2008, 83 5: 584-94.
[2] MANIACI C, CIULLI A. Bifunctional chemical probes inducing protein-protein interactions [J]. Current opinion in chemical biology, 2019, 52: 145-56.
[3] STEVERS L M, SIJBESMA E, BOTTA M, et al. Modulators of 14-3-3 Protein–Protein Interactions [J]. Journal of Medicinal Chemistry, 2017, 61: 3755 - 78.
[4] YANG J, LI Y, AGUILAR A, et al. Simple Structural Modifications Converting a Bona Fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders [J]. Journal of medicinal chemistry, 2019.
[5] MATYSKIELA M E, LU G, ITO T, et al. A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase [J]. Nature, 2016, 535: 252-7.
[6] BRITO M, MALTA-VACAS J, CARMONA B H M, et al. Polyglycine expansions in eRF3/GSPT1 are associated with gastric cancer susceptibility [J]. Carcinogenesis, 2005, 26 12: 2046-9.
[7] TOURE M, CREWS C M. Small-Molecule PROTACS: New Approaches to Protein Degradation [J]. Angewandte Chemie, 2016, 55 6: 1966-73.
[8] SCHAPIRA M, CALABRESE M F, BULLOCK A N, et al. Targeted protein degradation: expanding the toolbox [J]. Nature Reviews Drug Discovery, 2019, 18: 949 - 63.
[9] BAEK K, SCHULMAN B A. Molecular glue concept solidifies [J]. Nature Chemical Biology, 2019, 16: 2-3.
[10] GAVORY G, GHANDI M, D’ALESSANDRO A-C, et al. Abstract 3929: Identification of MRT-2359 a potent, selective and orally bioavailable GSPT1-directed molecular glue degrader (MGD) for the treatment of cancers with Myc-induced translational addiction [J]. Cancer Research, 2022.
[11] GAVORY G, GHANDI M, D’ALESSANDRO A-C, et al. Abstract 3449: Development of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for the treatment of lung cancers with MYC-induced translational addiction [J]. Cancer Research, 2023.
[12] STEIN E M, TALLMAN M S. Emerging therapeutic drugs for AML [J]. Blood, 2016, 127 1: 71-8.
[13] NAIR S K, BORA-SINGHAL N, PERUMAL D, et al. Nicotine-mediated invasion and migration of non-small cell lung carcinoma cells by modulating STMN3 and GSPT1 genes in an ID1-dependent manner [J]. Molecular Cancer, 2014, 13: 173 -
[14] COSTA-MATTIOLI M, WALTER P. The integrated stress response: From mechanism to disease [J]. Science, 2020, 368.
[15] SUH W-K, GAJEWSKA B U, OKADA H, et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responses [J]. Nature Immunology, 2003, 4: 899-906.
[16] PRASAD D V R, NGUYEN T, LI Z-X, et al. Murine B7-H3 Is a Negative Regulator of T Cells1 [J]. The Journal of Immunology, 2004, 173: 2500 - 6.
[17] CASTRICONI R, DONDERO A, AUGUGLIARO R, et al. Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis [J]. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101 34: 12640-5.
[18] STEINBERGER P, MAJDIC O, DERDAK S, et al. Molecular Characterization of Human 4Ig-B7-H3, a Member of the B7 Family with Four Ig-Like Domains1 [J]. The Journal of Immunology, 2004, 172: 2352 - 9.
[19] WANG C, LI Y, JIA L, et al. CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance [J]. Cell stem cell, 2021.
[20] JIN M-Z, JIN W-L. The updated landscape of tumor microenvironment and drug repurposing [J]. Signal Transduction and Targeted Therapy, 2020, 5.